



RIVAROXABAN Oral Suspension

- **Indicated for** prevention and treatment of deep vein thrombosis, stroke, pulmonary embolism and other thromboembolic events
- **Posology:** food administration the same as for Rivaroxaban tablets

Available strength: 5mg/ml in 150ml bottle

Easy to swallow

- The product is suitable for older patients with swallowing difficulties
- Also appropriate for administration via naso gastric tube
- Convenient administration, pleasant taste (strawberry flavour)

Coverage of three tablet strengths within one suspension

- Simplification of treatment and prevention of deep vein thrombosis and pulmonary embolism
- Easier dosing regimen which enables switching between doses

Product for patients with swallowing difficulties or naso gastric tube

Ready-to-use suspension for adults

Easy dose via oral syringe



Regulatory pathway

- Reference medicinal product: Xarelto, film-coated tablets
- Legal basis: Article 10(3) hybrid application
- CE-marked syringe enables precise dosing

Development status

- Prototypes developed and stability data available
- Pivotal bio-equivalency study available from Q4/2022
- EU dossier available from Q4/2022

Partnership options

- Product is available for out-licensing in Europe
- Dossier can be adjusted to markets outside Europe based on request

DISCLAIMER: Any disposal with the product, including but not limited to the development, sale and offer for sale of products and related processes identified within this catalogue is performed by Zentiva only in those territories where it is permissible by applicable patent law; in particular, but not limited to Art. 10 EC Directive 2001/83. This catalogue shall not constitute an offer for sale of products and processes for the territories where an offer for sale or sale is not permissible by law. Zentiva expressly disclaims any liability for damages resulting from or arising out of the unauthorised use of such products and related processes.